Targeted oral fixed-dose combination of amphotericin B-Miltefosine for visceral leishmaniasis (2025)
Source: Molecular Pharmaceutics. Unidade: FM
Subjects: FÁRMACOS, LEISHMANIA, FÁRMACOS IMUNOESTIMULANTES
ABNT
GARCIA, Raquel Fernandez et al. Targeted oral fixed-dose combination of amphotericin B-Miltefosine for visceral leishmaniasis. Molecular Pharmaceutics, v. 22, n. 3, p. 1437-1448, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/85240. Acesso em: 25 jan. 2026.APA
Garcia, R. F., Walsh, D., O'connell, P., Passero, L. F. D., Jesus, J. A. de, Laurenti, M. D., et al. (2025). Targeted oral fixed-dose combination of amphotericin B-Miltefosine for visceral leishmaniasis. Molecular Pharmaceutics, 22( 3), 1437-1448. doi:10.1021/acs.molpharmaceut.4c01133NLM
Garcia RF, Walsh D, O'connell P, Passero LFD, Jesus JA de, Laurenti MD, Dea Ayuela MA, Ballesteros MP, Lalatsa A, Bolas Fernandez F. Targeted oral fixed-dose combination of amphotericin B-Miltefosine for visceral leishmaniasis [Internet]. Molecular Pharmaceutics. 2025 ; 22( 3): 1437-1448.[citado 2026 jan. 25 ] Available from: https://observatorio.fm.usp.br/handle/OPI/85240Vancouver
Garcia RF, Walsh D, O'connell P, Passero LFD, Jesus JA de, Laurenti MD, Dea Ayuela MA, Ballesteros MP, Lalatsa A, Bolas Fernandez F. Targeted oral fixed-dose combination of amphotericin B-Miltefosine for visceral leishmaniasis [Internet]. Molecular Pharmaceutics. 2025 ; 22( 3): 1437-1448.[citado 2026 jan. 25 ] Available from: https://observatorio.fm.usp.br/handle/OPI/85240
